Luo Dakui, Fan Hao, Ma Xiang, Yang Chao, He Yu, Ge Yugang, Jiang Mingkun, Xu Zekuan, Yang Li
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Front Oncol. 2021 Apr 27;11:664242. doi: 10.3389/fonc.2021.664242. eCollection 2021.
So far, many existing evidences indicate that microRNAs (miRNA) are closely associated with the tumorigenesis and progression of various tumors. It has been reported that miR-1301-3p is abnormally expressed in several malignant tumors. However, the role of miR-1301-3p in gastric cancer (GC) remains unclear and is worth studying. Through qRT-PCR, the expression of miR-1301-3p and SIRT1 were detected in GC tissues and cells. The cell proliferation and cell cycle were measured through CCK-8 assay and clone formation assay. Dual luciferase reporter assay was used to determine the target of miR-1301-3p. Though tumorigenesis assay, we monitored the effect of miR-1301-3p on GC cell growth . miR-1301-3p was upregulated in GC tissues and cells in our study. Overexpression of miR-1301-3p accelerated GC cell proliferation, cell cycle progression and tumorigenesis. Notably, altering the expression miR-1301-3p caused deregulation of Cyclin D1, CDK4, c-Myc and P21. Furthermore, SIRT1 was the direct target of miR-1301-3p by luciferase reporter assay. After transfecting with miR-1301-3p inhibitor, we found that knockdown of SIRT1 could enhance the ability of proliferation. Our results identify miR-1301-3p as a novel potential therapeutic target that is associated with the tumorigenesis and progression of gastric cancer.
到目前为止,许多现有证据表明,微小RNA(miRNA)与各种肿瘤的发生和发展密切相关。据报道,miR-1301-3p在几种恶性肿瘤中异常表达。然而,miR-1301-3p在胃癌(GC)中的作用仍不清楚,值得研究。通过qRT-PCR检测GC组织和细胞中miR-1301-3p和SIRT1的表达。通过CCK-8测定法和克隆形成测定法测量细胞增殖和细胞周期。使用双荧光素酶报告基因测定法确定miR-1301-3p的靶标。通过肿瘤发生测定,我们监测了miR-1301-3p对GC细胞生长的影响。在我们的研究中,miR-1301-3p在GC组织和细胞中上调。miR-1301-3p的过表达加速了GC细胞增殖、细胞周期进程和肿瘤发生。值得注意的是,改变miR-1301-3p的表达导致细胞周期蛋白D1、细胞周期蛋白依赖性激酶4、c-Myc和P21失调。此外,通过荧光素酶报告基因测定,SIRT1是miR-1301-3p的直接靶标。在用miR-1301-3p抑制剂转染后,我们发现敲低SIRT1可以增强增殖能力。我们的结果确定miR-1301-3p是一种与胃癌发生和发展相关的新型潜在治疗靶点。